Biopharma buffers are solutions used to maintain and control pH levels of biological samples and pharmaceutical products during manufacturing, purification, transportation and storage. Buffers help maintain optimal pH for life-sustaining processes of biologics like vaccines, antibodies and proteins.
The global Biopharma Buffer Market is estimated to be valued at US$ 3.68 billion in 2024 and is expected to exhibit a CAGR of 11% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends: The increasing demand for biologics has been a key driver augmenting growth of the biopharma buffer market over the past decade. Biologic drugs are in high demand for treatment of chronic diseases like cancer, diabetes and cardiovascular disorders. Growing geriatric population prone to chronic diseases and rising healthcare expenditures have encouraged development of novel biologics. According to International Federation of Pharmaceutical Manufacturers & Associations, the global biologics market was valued at US$ 263 billion in 2018 and is estimated to reach US$ 498 billion by 2025, growing at a CAGR of 8.4%. Rising biologics pipeline and demand is expected to drive significant consumption of biopharma buffers for maintaining pH levels during biologics production, storage and transportation in the upcoming years.
Strength: Biopharma buffer market is growing continuously owing to increasing demand for biopharmaceuticals. Growing biologics industry require stable buffer solutions to maintain optimum pH levels for drugs development and manufacturing.
Weakness: High costs associated with R&D, clinical trials and regulatory approvals of new buffer formulations pose challenges for small players and startups to enter this market. Stringent regulatory guidelines also increase compliance burden.
Opportunity: Emerging markets of Asia Pacific and Latin America provide new growth opportunities owing to improving healthcare infrastructure and increasing healthcare expenditure. Development of efficient production technologies can lower costs and enhance commercialization of newer buffer solutions.
Threats: Price wars among existing players and entry of generic buffer solutions impact revenues of innovator brands. Stringent environmental regulations regarding waste treatment of buffer solutions increase production costs.
The global biopharma buffer market demand is expected to witness high growth. The market size for 2024 is estimated to reach US$ 3.68 Bn registering a CAGR of 11% during the forecast period of 2023 to 2030.
Regional analysis reveals that North America dominates currently due to presence of major players and highest R&D spending on drug development. Asia Pacific is poised to grow at fastest pace owing to rising prevalence of chronic diseases, growing generics industry and improving healthcare infrastructure in India and China.
Key players operating in the biopharma buffer market are Digital Medics Pty. Ltd., Emperra GmbH E-Health Technologies, Bio-Rad Laboratories Inc., Merck KGaA and Lonza Group Ltd. These players are focusing on new product launches, capacity expansions and partnerships to strengthen their market position. Digital Medics recently received FDA approval for its dissolvable rapid delivery buffer tablets.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it